FOLH1 and prostate carcinoma: Due to its relatively high molecular weight compared to the current clinical gold-standard monomeric PSMA-11 and its intrinsically high binding to serum proteins, this radioconjugate exhibited extended circulation in the blood pool and a different biodistribution profile with lower kidney and higher liver uptake than PSMA-11 in animal studies as well as in preliminary PET/CT imaging in a prostate carcinoma patient.